A tissue systems pathology test has significant clinical utility to standardize management leading to improved health outcomes for barrett's esophagus patients with low-grade dysplasia

Aims Low-grade dysplasia (LGD) is a predictor of malignant progression in Barrett’s esophagus (BE). However, pathology review is prone to inter-observer variability. A tissue systems pathology test (TissueCypher, TSP-9) has been shown to outperform pathology review in risk-stratifying BE patients. This study evaluated the clinical utility of the TSP-9 test to improve management decisions and health outcomes for BE patients with community LGD.